Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

• DOI: 10.1200/jco.2002.11.017
• Publication Date: 2002-10-01T21:58:26Z
• Authors: Thomas E. Witzig; Ian W. Flinn; Leo I. Gordon; Christos Emmanoui...; Myron S. Czuczman; Mansoor N. Saleh; Larry Cripe; Gregory Wiseman; Teresa Olejnik; Pratik S. Multani; Christine A. White
• Keywords: Ibritumomab tiuxetan; Follicular lymphoma; Refractory (planetary science); Regimen

PURPOSE: Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin’s lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same antigen rituximab and has demonstrated efficacy rituximab-naïve NHL. This study evaluated ibritumomab treatment of rituximab-refractory follicular PATIENTS AND METHODS: Eligible patients were refractory to rituximab; this was defined no objective response (375 mg/m 2 weekly 4 weeks) time progression (TTP) ≤ 6 months. The regimen consisted pretreatment with (250 intravenously on days 1 8) deplete peripheral blood B cells, then yttrium-90 (0.4 mCi/kg; maximum, 32 mCi) day 8, administered an outpatient basis. An imaging/dosimetry dose indium-111 (5 injected after (day 1) 28 patients. RESULTS: Fifty-seven treated. median age 54 years, 74% had tumors ≥ 5 cm, all extensively pretreated (median, four prior therapies; range, one nine). estimated radiation-absorbed doses healthy organs below study-defined limit studied dosimetry. overall rate NHL (15% complete responses 59% partial responses). Kaplan-Meier–estimated TTP 6.8 months (range, 1.1 25.9 months) 8.7 responders. Adverse events primarily hematologic; incidence grade neutropenia, thrombocytopenia, anemia 35%, 9%, 4%, respectively. CONCLUSION: effective only significant toxicity hematologic.